Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534637 · ClinicalTrials.gov registry record · Phase 2
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01534637 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 22 participants.
The verdict
NCT01534637, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer. Antiemetic drugs, such as aprepitant may help lessen or prevent nausea and vomiting in patients receiving chemotherapy and radiation therapy
Interventions
- DRUG fluorouracil
- DRUG capecitabine
- DRUG gemcitabine hydrochloride
- DRUG aprepitant
- PROCEDURE radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01534637
The ClinicalTrials.gov registry entry for NCT01534637 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fluorouracil is the first listed.
NCT01534637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01534637 about?
NCT01534637 is a clinical study titled "Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer". This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer. Antiemetic drugs, such as aprepitant may help lessen or prevent nausea and vomiting in patients receiving chemotherapy an...
What is the current status of trial NCT01534637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01534637?
The interventions under investigation include: fluorouracil (DRUG), capecitabine (DRUG), gemcitabine hydrochloride (DRUG), aprepitant (DRUG), radiation therapy (PROCEDURE).
Who is sponsoring clinical trial NCT01534637?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.